UK-based AI precision biotechnology company PrecisionLife has closed its first Series A funding round (amount undisclosed). The financing round is ongoing and is expected to close for the second time within the upcoming months.
The proceeds will be directed towards improving the company’s combinatorial analytics platform by incorporating new features including a drug repurposing solution and establishing an in-house drug pipeline. The funds will also be used to grow the team and fuel its R&D partnerships.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.